Product Images Aripiprazole
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 9 images provide visual information about the product associated with Aripiprazole NDC 53002-2765 by Rpk Pharmaceuticals, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
figure - aripiprazole fig1
This text discusses the effects of various drugs on Aripiprazole, including CYP3A4 inhibitor Ketoconazole, CYP2D6 inhibitor quinidine, enzyme inducer carbamazepine, gastric acid blocker famotidine, anticonvulsant valproate, and sedative lorazepam. The text provides information on the fold change and 90% confidence interval for Aripiprazole when used in combination with these medications.*
figure - aripiprazole fig2
This text provides information on the effects of various drugs on the metabolism of Aripiprazole, including CYP3A4 Inhibitor Ketoconazole, CYP2D6 Inhibitor Quinidine, CYP3A Inducer Carbamazepine, Gastric Acid Blocker Famotidine, and other drugs like Valproate and Lorazepam. It also mentions parameters like AUC (area under the curve), Cmax (maximum concentration), and Dehydro-Aripiprazole Fold Change with relative changes compared to a reference scenario.*
figure - aripiprazole fig3
This text discusses the effect of Aripiprazole on various drugs, presenting data on fold change and confidence intervals for drugs such as dextromethorphan, warfarin, omeprazole, lamotrigine, valproate, and others. The study provides insight into how Aripiprazole may impact the pharmacokinetics of these drugs.*
figure - aripiprazole fig4
figure - aripiprazole fig5
Figure 6: Kaplan-Meier Estimation of Cumulative Proportion of patients with Relapse (Schizophrenia Study 5) - aripiprazole fig6
Description: The text contains data related to the Kaplan-Meier estimation of the cumulative proportion of patients with relapse in a schizophrenia study. It provides information on the number of subjects at risk for both the Aripiprazole and Placebo groups, as well as the proportion of patients with relapse for each group over a certain period of time. The information includes days from randomization and the corresponding values for each group.*
Figure 9: Least Square Means of Change from Baseline in YGTSS TTS by Week (Tourette’s Disorder Study 1) - aripiprazole fig7
This is a comparison chart showing the change in YGTSS total TIC score from the baseline for aripiprazole low, aripiprazole high, and placebo over different weeks of treatment. The data indicates the least-squares mean change in YGTSS total TIC score over time for each treatment group.*
Aripiprazole Structure - aripiprazole str
Label Image - lbl530022765
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.